Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$67.59 -4.7%	$64.75	$47.86 ▼ $107.37	$3.91B	0.28	605,441 shs	538,450 shs
AVXL Anavex Life Sciences	$10.98 -0.7%	$8.98	$4.93 ▼ $14.44	$944.71M	0.72	1.19 million shs	762,981 shs
MRUS Merus	$63.26 +3.0%	$52.47	$33.19 ▼ $63.43	$4.25B	1	733,104 shs	1.06 million shs
ZLAB Zai Lab	$33.57 -6.8%	$34.64	$16.01 ▼ $44.34	$4.00B	0.99	917,358 shs	858,756 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	-4.74%	-2.02%	+5.91%	+8.98%	+3.18%
AVXL Anavex Life Sciences	-0.72%	-1.17%	+21.59%	+22.68%	+85.47%
MRUS Merus	+2.96%	+16.07%	+20.29%	+46.91%	+11.87%
ZLAB Zai Lab	-6.78%	+2.57%	-9.10%	+16.40%	+79.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.5401 of 5 stars	3.5	2.0	0.0	3.1	2.5	0.0
AVXL Anavex Life Sciences	3.9193 of 5 stars	3.7	1.0	4.7	2.5	0.8	0.6
MRUS Merus	1.9294 of 5 stars	3.6	1.0	0.0	2.0	2.5	0.0
ZLAB Zai Lab	3.3156 of 5 stars	3.4	5.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.07	Buy	$111.23	64.57% Upside
AVXL Anavex Life Sciences	3.33	Buy	$44.00	300.73% Upside
MRUS Merus	3.14	Buy	$84.64	33.79% Upside
ZLAB Zai Lab	2.80	Moderate Buy	$54.28	61.68% Upside

Current Analyst Ratings Breakdown

Latest AVXL, ACLX, MRUS, and ZLAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	ZLAB Zai Lab	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$73.00 ➝ $75.00
6/17/2025	ACLX Arcellx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$110.00
6/16/2025	ACLX Arcellx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/9/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$133.00 ➝ $93.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
4/28/2025	MRUS Merus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$107.94M	34.51	N/A	N/A	$8.41 per share	8.04
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
MRUS Merus	$36.13M	121.18	N/A	N/A	$9.46 per share	6.69
ZLAB Zai Lab	$398.99M	9.35	N/A	N/A	$7.68 per share	4.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$107.35M	-$2.99	N/A	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-40.93%	-36.38%	8/5/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
ZLAB Zai Lab	-$257.10M	-$2.49	N/A	N/A	N/A	-60.26%	-33.35%	-23.28%	8/7/2025 (Estimated)

Latest AVXL, ACLX, MRUS, and ZLAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACLX Arcellx	-$1.03	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q1 2025	MRUS Merus	-$1.17	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ZLAB Zai Lab	-$0.42	N/A	N/A	N/A	$125.66 million	N/A
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.93	4.93
AVXL Anavex Life Sciences	N/A	6.74	6.74
MRUS Merus	N/A	5.86	5.86
ZLAB Zai Lab	N/A	3.26	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
AVXL Anavex Life Sciences	31.55%
MRUS Merus	96.14%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
AVXL Anavex Life Sciences	11.40%
MRUS Merus	4.57%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
AVXL Anavex Life Sciences	40	85.42 million	75.68 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable
ZLAB Zai Lab	1,869	111.08 million	105.57 million	Optionable

AVXL, ACLX, MRUS, and ZLAB Headlines

Recent News About These Companies

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's Why

July 18 at 12:04 PM | marketbeat.com

C WorldWide Group Holding A S Sells 40,000 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 18 at 10:27 AM | marketbeat.com

Marks Group Wealth Management Inc Invests $373,000 in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 14, 2025 | marketbeat.com

Alps Advisors Inc. Sells 12,097 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 12, 2025 | marketbeat.com

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

July 10, 2025 | businesswire.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?

July 8, 2025 | marketbeat.com

67,159 Shares in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Bought by Penserra Capital Management LLC

July 8, 2025 | marketbeat.com

Principal Financial Group Inc. Purchases 1,121,856 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 5, 2025 | marketbeat.com

Ying Du Sells 7,072 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

July 3, 2025 | marketbeat.com

Cantor Fitzgerald Lowers Earnings Estimates for Zai Lab

July 3, 2025 | marketbeat.com

Leerink Partnrs Analysts Lift Earnings Estimates for Zai Lab

July 2, 2025 | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 6,918 Shares of Stock

July 2, 2025 | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $245,727.36 in Stock

July 1, 2025 | marketbeat.com

Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint

July 1, 2025 | finance.yahoo.com

Amgen, Zai Lab succeed in gastric cancer study

June 30, 2025 | msn.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of "Moderate Buy" by Analysts

June 30, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Price Target Raised to $75.00 at Leerink Partners

June 30, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

June 30, 2025 | marketbeat.com

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

June 30, 2025 | businesswire.com

Oppenheimer Asset Management Inc. Makes New Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

June 30, 2025 | marketbeat.com

Zai Lab (ZLAB) chief legal officer sells $212k in shares

June 29, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, ACLX, MRUS, and ZLAB Company Descriptions

Arcellx NASDAQ:ACLX

$67.59 -3.36 (-4.74%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$67.58 -0.01 (-0.01%)

As of 07/18/2025 04:34 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Anavex Life Sciences NASDAQ:AVXL

$10.98 -0.08 (-0.72%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.01 +0.03 (+0.27%)

As of 07/18/2025 07:51 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Merus NASDAQ:MRUS

$63.26 +1.82 (+2.96%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$63.24 -0.02 (-0.04%)

As of 07/18/2025 07:59 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Zai Lab NASDAQ:ZLAB

$33.57 -2.44 (-6.78%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$34.01 +0.44 (+1.30%)

As of 07/18/2025 07:32 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time